Companies · Other Health Care

RESTOR3D, Inc.

DURHAM · Other Health Care

Diligence memoA one-page analyst read on RESTOR3D, Inc. — recommendation, valuation, rhythm, risks.
$239.2M
Total raised · real
10
Rounds
4.2×
Latest step-up
Top 2%
Sector rank · raised
Series C
Latest stage · inferred · Fri Aug 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

RESTOR3D, Inc. looks over-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.31× the median modeled value of Series C Other Health Care companies in 2025–2027 (20 peers) — value vs value, same stage and era.
Active
  • Last raise 11 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

RESTOR3D, Inc. is one of 5377 Other Health Care companies tracked from DURHAM. By capital raised it ranks among the largest (ahead of 99% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
133
Investors (latest)
2025-08-08
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BPre-Seed · 2017-11-02 Raised $650K (real) Modeled valuation $20M (est)Pre-Seed2017Pre-Seed · 2018-05-01 Raised $385K (real) Modeled valuation $12M (est)Pre-Seed2018Series A · 2020-01-13 Raised $4.4M (real) Modeled valuation $88M (est)Series A2020Series A · 2020-01-13 Raised $4.9M (real) Modeled valuation $100M (est)Series A2020Series A · 2021-05-12 Raised $13M (real) Modeled valuation $193M (est)Series A2021Series A · 2022-03-01 Raised $14M (real) Modeled valuation $155M (est)Series A2022Series B · 2022-03-01 Raised $23M (real) Modeled valuation $307M (est)Series B2022Series B · 2023-05-10 Raised $12M (real) Modeled valuation $111M (est)Series B2023Series B · 2023-09-01 Raised $17M (real) Modeled valuation $143M (est)Series B2023Series B · 2024-01-22 Raised $21M (real) Modeled valuation $155M (est)Series B2024Series C · 2024-01-22 Raised $55M (real) Modeled valuation $504M (est)Series C2024Series A · 2025-01-15 Raised $6.3M (real) Modeled valuation $25M (est)Series A2025Series C · 2025-01-15 Raised $28M (real) Modeled valuation $202M (est)Series C2025Series B · 2025-01-15 Raised $25M (real) Modeled valuation $140M (est)Series B2025Series B · 2025-01-15 Raised $20M (real) Modeled valuation $111M (est)Series B2025Series C · 2025-08-08 Raised $85M (real) Modeled valuation $522M (est)Series C2025Cumulative $330M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$650K · 2017
Pre-Seed extension$385K · 2018
Series A$4.4M · 2020no Seed on file
Series A extension$4.9M · 2020
Series A extension$13.0M · 2021
Series A extension$13.9M · 2022
Series B$23.0M · 2022
Series B extension$12.0M · 2023
Series B extension$17.0M · 2023
Series B extension$20.7M · 2024
Series C$55.0M · 2024
Bridge · Series C-stage$6.3M · 2025smaller follow-on
Series C extension$28.4M · 2025
Bridge · Series C-stage$25.2M · 2025smaller follow-on
Bridge · Series C-stage$20.1M · 2025smaller follow-on
Series C extension$84.8M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 80%.

Modeled valuation trajectory
$522.3M
Base estimate est.
$308.3M
Conservative case
$682.0M
Upside case
$565.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $20.0M · 2017-11-022017Pre-Seed · modeled $11.9M · 2018-05-01Series A · modeled $88.5M · 2020-01-13Series A · modeled $99.6M · 2020-01-13Series A · modeled $192.7M · 2021-05-12Series A · modeled $154.9M · 2022-03-01Series B · modeled $306.8M · 2022-03-01Series B · modeled $111.3M · 2023-05-10Series B · modeled $143.3M · 2023-09-01Series B · modeled $155.2M · 2024-01-22Series C · modeled $503.7M · 2024-01-22Series A · modeled $24.8M · 2025-01-15Series C · modeled $201.9M · 2025-01-15Series B · modeled $139.7M · 2025-01-15Series B · modeled $111.1M · 2025-01-15Series C · modeled $522.3M · 2025-08-082025
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.29×/yr
Annual markup
1.48×/yr upside case
0.9 yr
Elapsed time used
0.9 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
6 mo
Avg between rounds
$30.8M/yr
Capital velocity
8.7 yr
On record since
2017
First round
16
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 98× above median
This company$239.2M
Sector median$2.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 1.8× above median
This company$84.8M
Sector median$45.9M
Modeled value — vs sector median (estimate, all stages) 24× above median
This company$522.3M
Sector median$22.1M

Raised more than 99% of sector peers (real $). Modeled value above 93% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #1 of 20.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)ByHeart, Inc. · Series C Raised $378.4M · modeled $493.6M (est)SpyGlassPharma, Inc. · Series C Raised $134.8M · modeled $485.1M (est)VantAI Holdings, Inc. · Series C Raised $86.3M · modeled $475.6M (est)BioIntelliSense, Inc. · Series C Raised $140.0M · modeled $329.0M (est)ObjectiveHealth, Inc. · Series C Raised $68.0M · modeled $321.2M (est)VentureMed Group, Inc. · Series C Raised $59.8M · modeled $288.2M (est)Exo Imaging, Inc. · Series C Raised $169.6M · modeled $284.6M (est)InspireMD, Inc. · Series C Raised $117.2M · modeled $248.3M (est)Fonar, Llc · Series C Raised $51.2M · modeled $229.0M (est)MicroTransponder, Inc. · Series C Raised $117.7M · modeled $223.3M (est)Fourth Edge LLC · Series C Raised $119.7M · modeled $222.0M (est)RESTOR3D, Inc. (this company) Raised $239.2M · modeled $522.3M (est)RESTOR3D, Inc.
CompanyStageRaised · realValue · estvs peer med.
RESTOR3D, Inc. this companySeries C$239.2M$522.3M2.31×
ByHeart, Inc.Series C$378.4M$493.6M2.18×
SpyGlassPharma, Inc.Series C$134.8M$485.1M2.14×
VantAI Holdings, Inc.Series C$86.3M$475.6M2.10×
BioIntelliSense, Inc.Series C$140.0M$329.0M1.45×
ObjectiveHealth, Inc.Series C$68.0M$321.2M1.42×
VentureMed Group, Inc.Series C$59.8M$288.2M1.27×
Exo Imaging, Inc.Series C$169.6M$284.6M1.26×
InspireMD, Inc.Series C$117.2M$248.3M1.10×
Fonar, LlcSeries C$51.2M$229.0M1.01×
MicroTransponder, Inc.Series C$117.7M$223.3M0.99×
Fourth Edge LLCSeries C$119.7M$222.0M0.98×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$650K2017-11-02$3.6M$20.0M90%
Pre-Seed$385K2018-05-01$2.1M$11.9M90%
Series A$4.4M2020-01-13$19.9M$88.5M90%
Series A$4.9M2020-01-13$22.4M$99.6M90%
Series A$13.0M2021-05-12$59.1M$192.7M90%
Series A$13.9M2022-03-01$63.3M$154.9M90%
Series B$23.0M2022-03-01$127.8M$306.8M90%
Series B$12.0M2023-05-10$66.7M$111.3M90%
Series B$17.0M2023-09-01$94.4M$143.3M90%
Series B$20.7M2024-01-22$115.3M$155.2M90%
Series C$55.0M2024-01-22$366.7M$503.7M90%
Series A$6.3M2025-01-15$28.5M$24.8M90%
Series C$28.4M2025-01-15$189.2M$201.9M90%
Series B$25.2M2025-01-15$140.0M$139.7M90%
Series B$20.1M2025-01-15$111.4M$111.1M90%
Series C$84.8M2025-08-08$565.5M$522.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$650K2017-11-02
    • First recorded raise — entered as Pre-Seed.
    • 11 investors on this round.
  2. Pre-Seed$385K2018-05-01
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 1.7× smaller than the prior — bridge or down round.
    • 10 investors on this round.
  3. Series A$4.4M2020-01-13
    • Raised again after 20 mo — slower than the ~14 mo sector norm.
    • Round 11.4× larger than the prior — scaling up.
    • 48 investors on this round.
  4. Series A$4.9M2020-01-13
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 48 investors on this round.
  5. Series A$13.0M2021-05-12
    • Raised 16 mo later, in step with the ~14 mo sector norm.
    • Round 2.6× larger than the prior — scaling up.
    • 101 investors on this round.
  6. Series A$13.9M2022-03-01
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 147 investors on this round.
  7. Series B$23.0M2022-03-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.7× larger than the prior — scaling up.
    • 202 investors on this round.
  8. Series B$12.0M2023-05-10
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 1.9× smaller than the prior — bridge or down round.
    • 96 investors on this round.
  9. Series B$17.0M2023-09-01
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
    • 98 investors on this round.
  10. Series B$20.7M2024-01-22
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 104 investors on this round.
  11. Series C$55.0M2024-01-22
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.7× larger than the prior — scaling up.
    • 150 investors on this round.
  12. Series A$6.3M2025-01-15
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 8.8× smaller than the prior — bridge or down round.
    • 49 investors on this round.
  13. Series C$28.4M2025-01-15
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.5× larger than the prior — scaling up.
    • 127 investors on this round.
  14. Series B$25.2M2025-01-15
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 111 investors on this round.
  15. Series B$20.1M2025-01-15
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 97 investors on this round.
  16. Series C$84.8M2025-08-08
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 4.2× larger than the prior — scaling up.
    • 133 investors on this round.
Intelligence
2026 ~Q1
Modeled next raise · ~6mo cadence
$254.5M
Modeled next size est.range $165.4M$407.2M
4.2×
Last step-up
$30.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Andrew Miller7 other2017-11
Kenneth Gall4 other2017-11
Kurt Jacobus4 other2017-11
Douglas Kohrs3 other2024-01
Ken Gall3 other2020-01
ANDREW SUMMERS2 other2024-01
JAMES STUBBS2 other2020-01
Michael Porter2 other2024-01
Brian Garvey1 other2022-03
Cambre Kelly1 other2023-05
William Rhoda1 other2022-03
Andrew Todd Miller2018-05
Bill Rhoda2023-05
Brian Neiswender2020-01
Erich E. Wolff2025-08
Greg Anglum2023-05
Ken Todd Gall2018-05
Kurt Todd Jacobus2018-05
Lawrence Boyd2023-05
Michael Fillion2025-01
Steve Joung2020-01
Steven Joung2023-05
Stuart E. Huston2025-01
Stuart Huston2024-01
Registry & provenance

RESTOR3D, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1723907
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
CurvaFix, Inc.Other Health CareSeries C$50.7M$478.1Mnetwork1 shared operator · same sector · same stage
Huxley Medical, Inc.HealthtechSeries A$32.7M$29.7Mnetwork3 shared operators
Relievant MedSystems IncOther Health CareSeries C$200.1M$523.3Msame sector · same stage
Fractyl Laboratories Inc.Other Health CareSeries C$290.1M$309.8Msame sector · same stage
ITC Nexus Holding Company, Inc.Other Health CareSeries C$191.8M$353.7Msame sector · same stage
NantCell, Inc.Other Health CareSeries C$301.6M$685.9Msame sector · same stage
Moximed, IncOther Health CareSeries C$187.8M$499.6Msame sector · same stage
ExploraMed NC7, Inc.Other Health CareSeries C$181.5M$752.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Protect3d, Inc.Other Health CareSeed$7.5M87%
Restor Metabolix IncOther Health CareSeed$9.3M87%
3DIO Inc.Other Health CarePre-Seed$1.5M84%
Restoria Health, Inc.HealthtechPre-Seed$6.0M83%
Dror Ortho-Design, Inc.Other Health CareSeries C$638.1M82%
3Derm Systems, Inc.Software / TechSeed$17.0M82%
OrthoPreserve, Inc.Other Health CarePre-Seed$327K81%
3Aware, Inc.Other Health CareSeed$3.4M81%
Frequently asked
How much funding has RESTOR3D, Inc. raised?
RESTOR3D, Inc. has raised approximately $239.2M in disclosed capital across 10 recorded financing rounds, aggregated from public filings.
What is RESTOR3D, Inc.'s estimated valuation?
Provath's modeled valuation for RESTOR3D, Inc. is approximately $522.3M (modeled range $308.3M–$682.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is RESTOR3D, Inc. at?
RESTOR3D, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Fri Aug 08.
What does RESTOR3D, Inc. do and where is it based?
RESTOR3D, Inc. operates in the Other Health Care sector, based in DURHAM.
Explore related

See where RESTOR3D, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at RESTOR3D, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.